Sorafenib - Mechanism of Action in treating Advanced Hepatocellular Carcinoma

Sorafenib / Nexavar is approved by the FDA for the treatment of renal cell carcinoma. As a result of recent trials in treating solid tumours like HCC.

Sorafenib when combined with the conventional transarterial chemoembolization improved time for progression, tumour response rate and progression-free survival when compared to treatment with Sorafenib alone.

Source: https://shorturl.at/fmBCU

#Sorafenib
#HepatocellularCarcinoma
#LiverCancer
#cancertreatment
#TargetedTherapy
#MechanismOfAction
#AntiAngiogenesis
#MultikinaseInhibitor
#TyrosineKinaseInhibitor
#AdvancedCancer
#PrecisionMedicine
#Oncology
#medicalresearch